Multicenter EXCYTE-2 Study to Evaluate the Precision Medicine Platform in Patients With Acute Myeloid Leukemia
Exscientia plc announced the launch of EXCYTE-2, an observational clinical trial in acute myeloid leukemia (AML), known as. This study aims to examine the relationship between ex vivo drug response (EVDR), measured on individual cells in primary blood or bone marrow samples using the company’s deep learning platform for precision medicine, and the actual clinical response of the patients.
The EXCYTE-2 study will collect blood and bone marrow samples from patients with AML in first-line therapy. There is an option to expand the study to include patients in second-line therapy. Both patient groups represent areas with high unmet medical needs and low survival rates. Biobanked tissue samples are collected from the treatment centers along with patient clinical data, including diagnostic and treatment results, and the samples are processed by Exscientia or partner laboratories. These partner laboratories will use Exscientia’s cloud-based AI to analyze the samples remotely.
The study also enables the assessment of the activity of EXS74539 (‘539), Exscientia’s LSD1 inhibitor, in a large, clinically annotated sample set. This study has the potential to support the ongoing development of ‘539, particularly in the selection of patients for future clinical trials.
Also Read: Helio Genomics Appoints Gary Frazier as Chief Growth Officer for the Early Cancer Detection Company
The EXCYTE-2 study builds on other ongoing precision medicine studies, including EXALT-1 and EXCYTE-1. The EXALT-1 study was an interventional study and the first study to use drug response analysis in primary human cancer tissue using high-content imaging and deep learning to guide treatment selection and improve patient outcomes to improve late-stage hematological cancers. EXCYTE-2 will leverage the advances the company has made in its AI-driven precision medicine platform since completing the EXALT-1 trial, specifically studying earlier-stage patient populations. EXCYTE-1 is an ongoing prospective observational study focused on ovarian cancer.
“This study continues our focus on establishing AI-driven ex-vivo drug testing in human tissue samples as the most comprehensive strategy for preclinical testing of novel therapies, complementary to mouse and other animal models,” said Dr. Nikolaus Krall, EVP of Precision Medicine at Exscientia. “A robust correlation between results from our platform and clinical outcomes has the potential to influence clinical practice for the benefit of AML patients.”
SOURCE: BusinessWire
